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Abstract
Aims/hypothesis This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether
mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications,
to prevent type 2 diabetes.
Methods The study was performed in people with prediabetes (n= 2062; control: n= 1031; intervention: n= 1031) defined by HbA1c
≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and
women aged 35–55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40–74 years without
pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-
generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained
blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition
received supportive text messages using mobile phone SMSmessages 2–3 times per week. Participants were assessed at baseline and at
6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry,
biochemistry, dietary and physical activity changes, blood pressure and quality of life.
Results At the 2 year follow-up (n = 2062; control: n = 1031; intervention: n = 1031), in the intention-to-treat population the HR
for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95%CI 0.74, 1.07; p =
0.22). There were no significant differences in the secondary outcomes.
Conclusions/interpretation This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduc-
tion in the progression to diabetes in 2 years by lifestyle modification using SMS messaging.
Trial registration The primary study was registered on www.ClinicalTrials.gov (India, NCT01570946; UK, NCT01795833).
Funding The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.
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Introduction
The public health challenge of type 2 diabetes is set to worsen as
the prevalence rises from 425 million people globally in 2017 to
629 million by 2045 [1]. Diabetes is preceded by a period of
intermediate hyperglycaemia (prediabetes), during which lifestyle
interventions have been shown to reduce progression to diabetes
in several RCTs [2–4].
The interventions in the initial diabetes prevention RCTs were
labour intensive and difficult to scale up to reach large numbers of
people at risk. Simple and scalable approaches to educate and
motivate at-risk individuals to make behavioural changes using
mobile phone short message service (SMS) text messages have
been developed in several areas of preventive medicine [5–11]. In
a previous RCT in India, we demonstrated that the delivery of a
package of customised, tailored SMS messages based on the
transtheoretical model (TTM) of behaviour change was effective
compared with standard care, reducing the incidence of type 2
diabetes by 36% over 2 years [9]. In that RCT we recruited
working Asian Indian men with persistent prediabetes defined
as impaired glucose tolerance on two OGTTs. This method for
defining prediabetes (and for assessing progression to diabetes) is
time consuming for participants and the healthcare system and is
difficult to scale up at societal level.
In the current study, we wished to test the generalisability of
the results from the previous trial in India [9]. To do this, first, we
included women as well as men; second, as the previous study
was relatively small (537 participants), a larger number of partic-
ipants was recruited; third, we tested the intervention in two ethni-
cally and culturally different environments, India and the UK,
using similar primary and secondary outcomes in both countries,
with only minor differences reflecting the different populations
and settings; finally, we used a more pragmatic method than
glucose estimations to define hyperglycaemia, HbA1c, as recom-
mended by theWHO [12]. The protocol permitted a comparative
pooled analysis of outcomes from the two populations including
an exploration of reasons for potential heterogeneity in the results.
Methods
Study design and participants
The detailed protocol has been reported previously [13]. In
brief, a randomised, controlled clinical trial was conducted
over 2 years in people with prediabetes defined by an HbA1c
level of ≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%) (the high
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prediabetes range). Screening for possible participants took
place in workplaces in India and at National Health Service
(NHS) Health Checks and in primary care centres in the UK.
All participants received structured education for prediabetes
and the intervention group received, in addition, SMS
messages about lifestyle 2–3 times weekly during the trial.
Participants were monitored at baseline and at 6, 12 and
24 months, undertaking repeat assessment of HbA1c and
blood glucose levels and completing questionnaires (the
Euro quality of life 5 dimension 3 level [EQ-5D-3L], a recent
physical activity questionnaire [RPAQ], a TTM of behaviour-
al change questionnaire, and food frequency [UK] or 24 h
dietary recall [India]). Physical activity (by accelerometer;
ActiGraph GT3X+, ActiGraph, Pensacola, FL, USA) and
acceptability of the SMS were monitored at baseline and
during follow-up. The primary outcome was progression to
diabetes. The secondary outcomes included anthropometric
measurements, other cardiovascular risk factors and measures
of lifestyle behaviours.
Figure 1 shows the flow diagram of pre-screening, screen-
ing, enrolment and randomisation, and the numbers of partic-
ipants in the two countries. The total number of participants
included in the analysis was 2062 (1031 in the control group,
1031 in the intervention group).
Pre-screening and screening
In India, pre-screening to identify people at high risk of devel-
oping diabetes was undertaken between April of 2012 and
November of 2015 in Asian Indian men and women aged
35–55 years in Chennai and surrounding areas. The target
population was employees from public and private sector
organisations. Following a diabetes awareness programme,
participants with no personal history of diabetes or other major
physical or mental illness having three or more risk factors,
including age 35–55 years, BMI ≥23 kg/m2, waist circumfer-
ence ≥90 cm inmen and ≥80 cm in women, first degree family
history of type 2 diabetes, history of hypertension or predia-
betes, or habitual sedentary behaviour, were selected for
further screening using HbA1c [13]. Those with values in the
high prediabetes range [14, 15] (≥42 and ≤47 mmol/mol
[≥6.0% and ≤6.4%]) were invited to participate in the trial.
In the UK, pre-screening was conducted mainly using the
NHS Health Checks programme, which is a cardiovascular
and diabetes risk assessment offered routinely and free of
charge to people aged 40–74 years without pre-existing diabe-
tes, cardiovascular disease or kidney disease. The programme
operates in primary care; people who met the HbA1c entry
criteria (≥42 and ≤47 mmol/mol [≥6.0% and ≤6.4%]) were
invited to participate in the trial if they fulfilled the other entry
criteria. In some primary care centres, screening schemes
other than the NHS Health Checks programme were used.
Written, informed consent was obtained from all participants.
Randomisation and masking
Randomisation was performed in India using a computer-
generated sequence, to either individually tailored mobile
phone SMS messages supplementing baseline lifestyle advice
(intervention group) or to a control group that received only
the lifestyle modification advice at baseline (1:1).
Randomisation in the UK was performed by a commercial
organisation in random permuted blocks stratified by sex,
age and BMI. Written, informed consent was obtained from
the participants and in India permissions had also been obtain-
ed from the employers. In both countries, laboratory personnel
and investigators were blinded to the participants’ group allo-
cation until the end of the study. Staff involved in delivering
the intervention and the participants themselves were, by
necessity, not masked.
The study was registered on www.ClinicalTrials.gov
(India, NCT01570946; UK, NCT01795833). The trial was
registered separately in the two countries since the funding
was received from two different national agencies.
Procedures for text messages
At baseline, in both countries, all trial participants received
personalised education and motivation about healthy diet
and the benefits of enhanced physical activity. In addition,
the intervention group received regular SMS messages, typi-
cally 2–3 per week, to provide additional education and moti-
vation. The content of the messages provided by SMS was
similar in both countries. The messages used in the previous
study in India [9] were modified and expanded. In the UK, a
Patient and Public Involvement Group in the National
Institute for Health Research Clinical Research Network
provided input into the SMS message design and content.
The messages provided tips, suggestions and positive rein-
forcement for healthy behaviours including goal setting, phys-
ical activity, dietary planning and personal strategies for life-
style change. The message content was based on the TTM of
behavioural change [16], a stage-based concept categorised
by: precontemplation (not ready), contemplation (getting
ready), preparation (ready), action and maintenance. We
prepared an SMS database and grouped the messages to be
appropriate for each TTM stage.
There were 75–80 messages in each TTM stage. Messages
were sent to the participants based on the TTM staging performed
at each follow-up. The type and content of the messages were
changed frequently to avoid repetition. Messages were delivered
by commercial service providers. In India, messages were in
English and in two local languages and were sent between
06:30 hours and 08:30 hours or after 18:00 hours, as preferred
by the participants. In the UK, messages were sent at 10:00 hours
on alternate days. The preferred time was ascertained during the
follow-up visits so that the messages did not go unnoticed.
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Acceptability of SMS in the intervention group was
assessed using a short questionnaire [9]. Responses to ques-
tions about message content, frequency, ease of understand-
ing, whether messages were considered a disturbance and
whether they were perceived as helpful in improving lifestyle
were scored as 0 or 1. A total score of 6 was the most accept-
able and 0 the least. A modified acceptability questionnaire
was used in the UK.
Lifestyle and quality of life
Diet At baseline, individualised dietary recommendations
were delivered to balance food intake and physical activity,
and to aim for an appropriate body weight. Advice included:
avoidance of simple sugars and refined carbohydrates, reduc-
tion of total fat intake (<20 g/day) and inclusion of increased
fibre-rich food (e.g. whole grains, legumes, vegetables and
fruits). Evaluation was performed using 24 h dietary recall, a
method used previously in India [9]. In the UK arm, a food
frequency questionnaire was used for calculation of dietary
energy intake and major food constituents [17], a method
previously validated against 24 h dietary recall [18].
Physical activity Participants who reported being sedentary or
who undertook only light physical activity at baseline were
advised to walk briskly every day for a minimum of 30 min.
People who reported strenuous occupations or sufficient phys-
ical activity per day were advised to continue these activities.
Physical activity was assessed by self-report using the RPAQ,
which has previously been shown to provide a valid estimate
of physical activity energy expenditure (PAEE), measured by
the gold standard criterion method of doubly labelled water
and time spent in different intensity levels [19]. We also
assessed physical activity objectively using triaxial
accelerometry (ActiGraph GT3X+) which has also been vali-
dated against criterion methods [20, 21].
Lost to follow-up (n=149)
Died (n=1)
(acute hepatic failure with septic shock)
Unavailable (n=44)
(prescribed metformin treatment)
Not willing to continue (n=103)
Withdrawn from study (n=1)
Analysis
Analysed (n=1031)Analysed (n=1031)
Pre-screening in UK (n=10,790)
Mainly NHS health checks
Prediabetes by any criterion using FPG 
or HbA
1c
Pre-screening in India (n=6030)
Employees from public and private sector 
organisations
Excluded (n=11,314)
Did not meet inclusion criteria
Unwilling to participate
Unable to read SMS
Enrolment
Screened using HbA
1c
 (n=5506)
≥42 to ≤47mmol/mol
Randomised (n=2062)
India (n=1171; 887 men, 284 women)
UK (n=891; 432 men, 459 women)
Intervention (n=1031)
(SMS)
Control (n=1031)
(standard care)
Allocation
Follow-up
Lost to follow-up (n=150)
Died (n=2)
(cardiac arrest; rupture of aortic aneurysm)
Unavailable (n=49)
Not willing to continue (n=99)
Excluded (n=3444)
Did not meet HbA
1c
 criterion
Unwilling to participate
Fig. 1 CONSORT diagram of
trial profile. FPG, fasting plasma
glucose
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Quality of life The EQ-5D-3L version for India was adminis-
tered to capture the individuals’ ‘perceived’ quality of life
based on the effects of the health intervention [22].
The questionnaire consists of five dimensions (mobility,
self-care, usual activities, pain/discomfort, anxiety/depres-
sion) and the responses record three levels of severity (no
problems/some or moderate problems/extreme problems)
within each dimension. The EQ-5D-3L summary measure
was calculated using a value set derived from a UK sample
since there are no published value sets in Indian populations.
Biochemical assessments
During the baseline and at each review, anthropometry, blood
pressure (mean of two readings using sphygmomanometer),
HbA1c and serum lipid profile (total cholesterol, low density
lipoprotein, HDL-cholesterol and triacylglycerols) were
measured using standard enzymatic procedures with quality
control.
Ethics approvals
In India, the Ethics Review Committee of the India Diabetes
Research Foundation and Dr. A. Ramachandran’s Diabetes
Hospitals reviewed and approved the study protocol. An inde-
pendent safety committee assessed study progress with
unmasked data at 6 month intervals. In the UK, approval
was from the Westminster Research Ethics Committee and
site specific assessment (SSA) plus research and development
(R&D) approvals were in place at each participating NHS
Trust. Imperial College Academic Health Science Centre
acted as the main sponsor. Delegated responsibilities were
assigned to the participating NHS trusts.
Outcomes
In the UK, the primary outcome was progression to diabetes
as defined by international criteria for fasting plasma glucose
or HbA1c at any study review visit or in any healthcare setting.
In India, information from study follow-up visits was avail-
able; thus, diabetes was defined on HbA1c alone.
The secondary outcomes were bodyweight and BMI, waist
circumference, blood pressure, fasting plasma glucose, lipid
levels, proportion achieving HbA1c ≤42 mmol/mol (≤6.0%),
acceptability of SMS, dietary variables, physical activity and
quality of life.
Statistical analyses
Based on results from the Indian Diabetes Prevention study
[9], a 2 year risk of diabetes in the control group of 25% was
assumed. With 2268 participants (1134 per group), the trial
had 80% power to detect a relative reduction in risk of 20% as
significant at the 5% level, allowing for approximately 4%
withdrawals.
Baseline characteristics were summarised by randomised
group using mean and standard deviation (continuous vari-
ables), median and interquartile range (continuous variables
with a skewed distribution), or frequency and percentage
(categorical variables).
The primary outcome was compared between intervention
and control groups using a discrete-time proportional hazards
model with a complementary log-log link function, since the
data were interval censored [23], adjusted for country. The
multiplicative interactions between randomised group and
(1) country and (2) sex were tested using a Wald test. The
HR for type 2 diabetes and 95% confidence intervals were
reported for the overall trial population, and separately by
country (UK/India) and sex, which were the only pre-
specified subgroups.
Secondary outcomes, measured at specified time points
during follow-up, were analysed using linear regression with
random intercepts at the individual level to allow for repeated
measures, including the baseline value of the outcome, country,
randomised group and time, to estimate an overall intervention
effect, and then also using randomised group × time interaction,
to estimate intervention effects at each follow-up time.
Accelerometer wear time was included in the model for objec-
tively measured physical activity outcomes. Outcomes with a
skewed distribution were log-transformed prior to analysis.
The trial was analysed on an intention-to-treat basis. The
primary outcome was also analysed in a per-protocol popula-
tion, which excluded individuals in whom the intervention
was not successfully delivered. All analyses were pre-
specified [13], and performed using Stata version 14.2
(Stata, College Station, TX, USA).
Results
Recruitment in India took place between 1 April 2012 and 1
November 2015, and in the UK between 1 June 2013 and 1
November 2017. Follow-up was for 2 years in both countries.
The numbers assessed at pre-screening and screening are
shown in Fig. 1. In the UK the recruitment took place in
multiple primary care settings, mainly using the NHS Health
Checks programme; routinely obtained data were scrutinised
for eligibility and individuals were asked to participate if they
fulfilled the entry criteria.
Primary and secondary outcomes
In total, 2062 participants were randomised (control: 1031; inter-
vention: 1031). Baseline characteristics were similar in the two
randomised groups (Table 1). The mean age was 52.0 (SD 10.3)
years, and 64.0% of the participants overall were men.
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During the 2 year follow-up period, 234 (22.7%) individ-
uals in the control group and 216 (21.0%) in the intervention
group developed diabetes. The cumulative percentage of indi-
viduals who developed diabetes at 6, 12 and 24 months in the
control and intervention groups is shown in Fig. 2. There was
no significant effect of the intervention on the primary
outcome (HR for intervention vs control 0.89; 95% CI 0.74,
1.07; p = 0.22) (Fig. 3).
The overall intervention effects on the secondary outcomes
are shown in Fig. 4 and in Table 2. Confidence intervals
around the estimated effects were wide and overlapped zero.
Mean values of most outcomes changed little between base-
line and any of the follow-up visits in either randomised
group.
For all of the secondary outcomes reported in Table 2, a
maximum of 1.3% of individuals had missing values at base-
line, except for work PAEE (22.6%), commuting PAEE
(22.5%), each of the three ActiGraph physical activity
measures (12.6%) and the EQ-5D-3L summary measure
(41.1%). The percentages of individuals with missing values
were similar in the two randomised groups. When estimating
intervention effects using random intercepts linear regression,
available data from all time points (including baseline) were
included in the model. This assumes that anymissing values at
either baseline or another time point were missing at random.
Within this trial, the correlation between total physical activ-
ity (ActiGraph, counts/min) and total PAEE (kJ kg−1 day−1,
RPAQ) was 0.28 at baseline and 0.32 at 24 months.
Although body weight did not change significantly, there
were reductions in estimated intakes of total energy, fat, carbo-
hydrates and protein, and an increase in estimated fibre intake,
Table 1 Baseline characteristics by randomised group
Variable Combined India and UK India UK
Control (n =
1031)
Intervention (n =
1031)
Control (n =
587)
Intervention (n =
584)
Control (n =
444)
Intervention (n =
447)
Sex
Men 661 (64.1%) 658 (63.8%) 445 (75.8%) 442 (75.7%) 216 (48.6%) 216 (48.3%)
Women 370 (35.9%) 373 (36.2%) 142 (24.2%) 142 (24.3%) 228 (51.4%) 231 (51.7%)
Age (years) 52.0 (10.2) 52.1 (10.3) 45.8 (5.4) 45.8 (5.4) 60.2 (9.3) 60.3 (9.4)
Weight (kg) 79.7 (15.6) 79.0 (15.4) 75.3 (10.8) 74.7 (10.7) 85.4 (18.9) 84.5 (18.5)
BMI (kg/m2) 28.9 (4.8) 28.7 (4.7) 27.9 (3.6) 27.5 (3.3) 30.2 (5.8) 30.2 (5.7)
Waist circumference
(cm)
97.8 (11.3) 97.5 (11.0) 95.5 (7.5) 95.1 (7.1) 100.8 (14.4) 100.7 (14.0)
Blood pressure (mmHg)
Systolic 129.3 (16.8) 128.8 (17.0) 127.1 (16.7) 126.8 (17.3) 132.2 (16.4) 131.3 (16.3)
Diastolic 81.5 (10.6) 81.0 (10.6) 82.5 (10.4) 82.1 (10.6) 80.1 (10.8) 79.6 (10.5)
HbA1c (mmol/mol) 43.6 (1.4) 43.6 (1.4) 43.5 (1.4) 43.6 (1.4) 43.8 (1.4) 43.8 (1.4)
HbA1c (%) 6.1 (0.1) 6.1 (0.1) 6.1 (0.1) 6.1 (0.1) 6.2 (0.1) 6.2 (0.1)
Fasting glucose (mmol/l) 5.5 (0.7) 5.5 (0.7) 5.4 (0.7) 5.4 (0.7) 5.6 (0.6) 5.6 (0.6)
Lipid profile (mmol/l)
Total cholesterol 4.9 (1.1) 4.9 (1.0) 4.7 (0.9) 4.7 (0.8) 5.2 (1.2) 5.2 (1.2)
HDL-cholesterol 1.2 (0.4) 1.2 (0.4) 1.0 (0.2) 1.0 (0.2) 1.5 (0.4) 1.4 (0.4)
LDL-cholesterol 3.0 (0.9) 3.1 (0.9) 3.0 (0.8) 3.0 (0.7) 3.1 (1.1) 3.1 (1.1)
Triacylglycerols 1.3 (1.0–1.8) 1.3 (1.0–1.8) 1.3 (1.0–1.7) 1.3 (1.0–1.7) 1.3 (0.9–1.8) 1.3 (0.9–1.8)
Data are mean (SD) or n (%) unless otherwise indicated
aMedian (interquartile range)
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as assessed by a self-report questionnaire in each group, and as
shown in Table 2.
The SMS acceptability questionnaire in India, where the
median score out of 6 was 3, showed that messages were
generally acceptable. Fewer than 5% of the participants
reported that receiving the messages was a disturbance. In
the UK the acceptability of SMS varied between 85% at
6 months to 82% at 24 months.
Over the 2 years of follow-up the observed percentages
developing diabetes in both intervention and control groups
were higher in India (control: 30.3%; intervention: 26.0%)
than in the UK (control: 12.6%; intervention: 14.3%). There
was no clear evidence of differential effects of the intervention
by country or sex (tests of multiplicative interaction:
randomised group × country: p = 0.33; randomised group ×
sex: p = 0.12) (Fig. 3).
Analysis of results per protocol in the intervention
and control arms
In the per-protocol analysis, the overall results were similar to
the intention-to-treat analysis for the primary outcome (HR for
intervention vs control 0.95; 95% CI 0.79, 1.16; p = 0.63) and
for the secondary outcomes.
Overall
Country
UK
India
Sex
Men
Women
HR (95% CI)
0.89 (0.74,1.07)
0.99 (0.69,1.43)
0.84 (0.68,1.05)
0.98 (0.79,1.22)
0.69 (0.48, 0.98)
0.4 0.8 1.0 1.6
Favours intervention Favours control
Fig. 3 Effect of intervention on
primary outcome (the
development of type 2 diabetes)
overall (p = 0.22) and by pre-
specified subgroups (intervention
× country interaction: p = 0.33;
intervention × sex interaction: p =
0.12)
Outcome
HbA
1c
 (%)
HbA
1c
 (mmol/mol)
Fasting glucose (mmol/l)
Weight (kg)
BMI (kg/m2)
Waist (cm)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Total cholesterol (mmol/l)
HDL-cholesterol (mmol/l)
LDL-cholesterol (mmol/l)
Triacylglycerol (log
e 
[mmol/l])
Total energy intake (kJ/day)
Fat (g/day)
Carbohydrates (g/day)
Protein (g/day)
Fibre (g/day)
Total PAEE (kJ kg−1 day−1)
Home PAEE (kJ kg−1 day−1)
Work PAEE (kJ kg−1 day−1)
Commuting PAEE (kJ kg−1 day−1)
Leisure PAEE (kJ kg−1 day−1)
Total physical activity (counts/min)
Time spent in MVPA (h)
Time spent in sedentary activity (h)
EQ-5D-3L
SD
0.1
1.4
0.7
15.5
4.7
11.2
16.9
10.6
1.1
0.4
0.9
0.4
2533.2
29.5
95.0
22.0
9.8
37.6
8.4
25.9
19.3
16.0
124.9
0.7
1.3
0.1
-0.4 -0.2 0 0.2 0.4
Intervention vs control group (SD units)
Fig. 4 Overall effect of
intervention on secondary
outcomes (n = 2062). Intervention
effects represent differences
between intervention and control
groups, estimated from a linear
regression model with random
intercepts at the individual level,
using measures of the outcome at
all follow-up times, and including
baseline value of the outcome,
country, randomised group and
time (months of follow-up).
Intervention effects are presented
in units of baseline SD of each
outcome. Triacylglycerol results
are presented using log-
transformed values. MVPA,
moderate-to-vigorous physical
activity
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Discussion
Although mobile technology is being widely applied in clin-
ical management of a variety of long-term chronic disorders
[6, 7, 10, 11, 24, 25] and also in modifying behaviour patterns
such as smoking [26], the number of randomised intermediate
and long-term studies in prevention of diabetes is limited. In
this 2 year RCT involving 2062 participants with prediabetes
recruited in two countries, India and the UK, with different
ethnic and socio-cultural backgrounds, we have shown that
delivery of a behavioural intervention by mobile technology
is feasible. However, there was a non-significant risk reduc-
tion in the rate of progression of diabetes in 2 years by lifestyle
modification using SMS messages.
A previous pilot trial of this intervention that we completed
in India alone did find evidence of an effect. However, there
are a number of differences between these trials that may
explain the inconsistency in findings. First, the former study
[9] was conducted in male employees of major industries,
whereas the current study included men and women recruited
from the general population. It is unlikely that it is the inclu-
sion of women, rather than men alone, that has led to this
inconsistency, since a pre-defined subgroup analysis provided
weak evidence that the intervention may yield benefit in
women. In other diabetes prevention studies, a major sex
effect has not been observed [27]. It is more likely that the
difference we observed is explained by the selected socio-
cultural make-up of the population in the original study
compared with the more population-based approach in the
current study.
Second, the former study was conducted at a time when
SMS messaging was novel in India and it is possible that this
novelty and the fact that the messages appeared to come from
a healthcare organisation may have influenced their effect.
More recently, SMS messaging in India has proliferated, not
only for the purpose of personal messaging, but also for mass
advertising. Thus, it is possible that in the more recent study
the ‘apparently personal’ targeted messaging that was previ-
ously effective is now just part of a slew of suchmessages, and
thus may not only be diluted in effect but could also, by being
of a similar nature to advertising, be considered an irritant.
Third, the way in which a high-risk prediabetes group was
identified was fundamentally different. In the previous study
we used the OGTT to define prediabetes and progression to
diabetes. This test, and in particular the 2 h glucose, is highly
variable and responsive to behaviour change [28], thus
making it an excellent way to identify those at risk and the
response to intervention. However, we sought not only to test
the effectiveness of the intervention, but to do that in a way
that was scalable. Unfortunately, the practicalities of the
OGTT make it impossible to scale up to a mass intervention.
Thus, we utilised the much more practical HbA1c test which
could theoretically be employed in a real-life intervention
programme to classify prediabetes and progression to diabe-
tes. Although HbA1c has similar biological significance to
other measures of glycaemia, for example, in terms of predic-
tion of cardiovascular events [29], a possible disadvantage
may be that, as an integrated measure of glucose control over
a period of time, HbA1c is less sensitive to behaviour risk
factor change, which may partially explain the lower estimate
of effect size in this study. Finally, this study, unlike the former
study, was conducted both in the UK and in India. It is possi-
ble that there could be country differences in the response to
such an intervention, for socio-cultural or other reasons. The
UK participants were recruited from primary care centres and
thus, by definition, were in contact with an organised system
of healthcare and would potentially have greater awareness of
the importance of healthy lifestyle behaviours. By contrast,
the participants in India are likely to have had less access to
primary care and thus potentially a lower pre-existing aware-
ness of health-promoting behaviours and a greater potential to
benefit from this form of individual-level targeted prevention
strategy.
Overall, the observed progression rate from prediabetes to
diabetes was greater in India than in the UK. The rate in India
is compatible with that in our previous Indian study [9] and the
approximately 50% lower progression rate in the UK is
consistent with other recent UK studies [30]. Previous analy-
sis of the Diabetes Prevention Program (DPP) intervention
within a single country has shown no differences in the risk
of progression to diabetes from prediabetes between ethnic
groups [31]. Our study shows that the rate of progression is
markedly different between countries. We were not able in a
pre-specified analysis to demonstrate significant differences in
any intervention effect between the two countries, but this
analysis may be under-powered to investigate differences in
a low effect size. The low incidence of diabetes in the UK arm
of this trial may have limited our ability to detect an effect of
the intervention. Nor were we able to demonstrate significant
differences in the secondary endpoints. Some of the apparent
improvements that were observed in self-reported dietary
components may be explained by reporting bias.
The results of this trial need to be set in the context of
results of intervention evaluations elsewhere. In a recent trial
in Denver, USA, Fischer et al evaluated text messaging as an
aid to achieving weight loss in individuals with prediabetes
[32]. Over 12 months, a clinically significant benefit in terms
of weight loss was observed in the intervention group, but at
1 year HbA1c levels did not differ between the groups. A
similar impact on weight was observed in a 12 month trial
of a low-intensity lifestyle programme in Australian women
[33], but although this intervention included monthly text
messages on healthy behaviour, these messages were deliv-
ered in addition to phone coaching and provision of a
programme manual, making it difficult to isolate the effect
of the messages alone.
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The utility of SMS in improving adherence to antiretroviral
therapy [34] and smoking cessation has also been reported [35].
In a recent study in Bangladesh, a community-based inter-
vention with facilitator-led group meetings was effective in
preventing type 2 diabetes when an SMS-based intervention
alone was not [36]. These studies and our own are compatible
with the conclusions from a recent systematic review of elec-
tronically delivered weight loss programmes [37] that elec-
tronic delivery of lifestyle advice and motivation alone may
be less effective than when supplemented with remote
counselling or counselling in person. Cultural differences
may also influence outcome and variability in results [24],
although no major differences were observed in our study
between effects in India and the UK.
Future studies should be powered to detect small intervention
effects which may not be meaningful at an individual level, but
which might be meaningful if scaled across a population level.
We would also suggest that studies should be established to
investigatemore thoroughly the contextual factors thatmay influ-
ence the effectiveness of this type of intervention.
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